SLI
2.010,74
PKT
-11,91
PKT
-0,59
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 09.11.17 | Givaudan neutral | Bernstein Research | |
| 09.11.17 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
| 09.11.17 | Zurich Insurance Underperform | Bernstein Research | |
| 08.11.17 | Novartis Hold | Deutsche Bank AG | |
| 08.11.17 | UBS buy | Citigroup Corp. | |
| 08.11.17 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 07.11.17 | Zurich Insurance Neutral | UBS AG | |
| 07.11.17 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
| 07.11.17 | Swiss Re overweight | JP Morgan Chase & Co. | |
| 07.11.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.11.17 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.11.17 | Zurich Insurance Hold | Deutsche Bank AG | |
| 06.11.17 | Swiss Re overweight | Morgan Stanley | |
| 06.11.17 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
| 06.11.17 | Roche overweight | JP Morgan Chase & Co. | |
| 06.11.17 | Swiss Re overweight | JP Morgan Chase & Co. | |
| 03.11.17 | UBS buy | Goldman Sachs Group Inc. | |
| 03.11.17 | Swiss Re Neutral | Goldman Sachs Group Inc. | |
| 03.11.17 | UBS overweight | Morgan Stanley | |
| 03.11.17 | UBS Hold | S&P Capital IQ | |
| 03.11.17 | Swiss Re overweight | JP Morgan Chase & Co. | |
| 03.11.17 | UBS kaufen | JP Morgan Chase & Co. | |
| 02.11.17 | Swiss Re kaufen | DZ BANK | |
| 02.11.17 | UBS buy | UBS AG | |
| 02.11.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 02.11.17 | Roche overweight | JP Morgan Chase & Co. | |
| 02.11.17 | UBS overweight | JP Morgan Chase & Co. | |
| 02.11.17 | Swiss Re Hold | Baader Bank | |
| 02.11.17 | Swiss Re Reduce | Commerzbank AG | |
| 01.11.17 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 01.11.17 | Holcim Hold | Deutsche Bank AG | |
| 01.11.17 | Holcim Neutral | UBS AG | |
| 01.11.17 | Holcim Hold | HSBC | |
| 01.11.17 | ABB (Asea Brown Boveri) buy | Kepler Cheuvreux | |
| 31.10.17 | Swiss Re Sell | UBS AG | |
| 31.10.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 31.10.17 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 31.10.17 | Novartis buy | HSBC | |
| 31.10.17 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 31.10.17 | Swiss Re Neutral | Goldman Sachs Group Inc. |